Clinical trials: Choroidal Neovascular Membrane
Macular Degeneration, Age-Related Maculopathies
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
- Trial name
- NCT01024998
- Testing
- AAV2-sFLT01
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Macular Degeneration, Choroidal Neovascularization
Phase II/III Study of Anti-VEGF in Neovascular AMD
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
- Trial name
- NCT00021736
- Testing
- EYE001 anti-VEGF aptamer
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals